title: Long-term results of treatment of macular complications in eyes with immune recovery uveitis using a graded treatment approach.
abstract: OBJECTIVE
  To evaluate the results of a graded treatment approach in a cohort of eyes with macular complications of immune recovery uveitis.
  
  
  METHODS
  A cohort of 18 eyes of 13 patients representing all eyes with these complications at the University of California, San Diego AIDS Ocular Treatment Unit was studied. Eyes were classified into three groups and treated according to a graded protocol.
  
  
  RESULTS
  Eyes with mild disease (macular edema and vision of 20/30 or better) were observed. These six eyes maintained good vision with only one dropping to 20/40. In eyes with worse macular edema and vision of 20/30 or worse (10 eyes of 9 patients), repository sub-Tenon steroid injections were used repeatedly. There were no complications of steroid use but visual improvement occurred in only 40% of eyes. Macular edema persisted. In eyes with structural macular changes, such as epiretinal membrane, vitrectomy resulted in vision improvement in three of four eyes. The cystoid macular edema persisted despite surgery.
  
  
  CONCLUSIONS
  Mild cases of immune recovery uveitis and macular edema may be observed. In eyes with reduction of vision due to cystoid macular edema, there was only a modest treatment effect using repository corticosteroids. Eyes with immune recovery uveitis that develop epiretinal membrane undergo some visual improvement after removal of the membrane. The macular edema of immune recovery uveitis is resistant to corticosteroid treatment.
authors.affiliation: Shiley Eye Center, San Diego, CA 92093-0946, USA.
authors.forename: Mohamed H
authors.initials: MH
authors.lastname: El-Bradey
authors.forename: Lingyun
authors.initials: L
authors.lastname: Cheng
authors.forename: Mi-Kyoung
authors.initials: MK
authors.lastname: Song
authors.forename: Francesca J
authors.initials: FJ
authors.lastname: Torriani
authors.forename: William R
authors.initials: WR
authors.lastname: Freeman
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000276:immunology; D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D003131:Combined Modality Therapy; D017726:Cytomegalovirus Retinitis / Q000150:complications / Q000276:immunology; D019773:Epiretinal Membrane / Q000209:etiology / Q000628:therapy*; D005128:Eye Diseases / Q000150:complications* / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008269:Macular Edema / Q000209:etiology / Q000628:therapy*; D008297:Male; D008775:Methylprednisolone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077555:Methylprednisolone Acetate; D008875:Middle Aged; D011379:Prognosis; D014605:Uveitis / Q000150:complications* / Q000276:immunology; D014821:Vitrectomy; D014822:Vitreous Body
chemical_list: D005938:Glucocorticoids; D000077555:Methylprednisolone Acetate; D008775:Methylprednisolone